

Lucrezia Hausner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11677690/publications.pdf>

Version: 2024-02-01

44
papers

3,720
citations

331259

21
h-index

301761

39
g-index

44
all docs

44
docs citations

44
times ranked

5535
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
2	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment" data from the Dementia Competence Network. <i>Journal of Neural Transmission</i> , 2022, 129, 477-486.	1.4	14
3	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
4	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	4.5	31
5	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	1.3	19
6	Crossed Cerebellar Diaschisis in Alzheimer's Disease Detected by Arterial Spin-labelling Perfusion MRI. <i>In Vivo</i> , 2021, 35, 1177-1183.	0.6	5
7	Evaluation of Sodium (²³ Na) MR-imaging as a Biomarker and Predictor for Neurodegenerative Changes in Patients With Alzheimer's Disease. <i>In Vivo</i> , 2021, 35, 429-435.	0.6	14
8	Rapid Support for Older Adults during the Initial Stages of the COVID-19 Pandemic: Results from a Geriatric Psychiatry Helpline. <i>Geriatrics (Switzerland)</i> , 2021, 6, 30.	0.6	1
9	Promoting neuroplasticity and neuropsychological functioning in frailty through an app-based sensorimotor training: study protocol for a randomized trial. <i>BMC Geriatrics</i> , 2021, 21, 343.	1.1	3
10	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
11	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 349-356.	0.9	31
12	Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 124.	3.0	12
13	Bupropion for the Treatment of Apathy in Alzheimer Disease. <i>JAMA Network Open</i> , 2020, 3, e206027.	2.8	18
14	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2020, 19, 1310-1318.	1.8	43
15	Case report: a giant arachnoid cyst masking Alzheimer's disease. <i>BMC Psychiatry</i> , 2019, 19, 274.	1.1	7
16	Tablet-based sensorimotor home-training system for amnesic mild cognitive impairments in the elderly: design of a randomised clinical trial. <i>BMJ Open</i> , 2019, 9, e028632.	0.8	5
17	Separating Symptomatic Alzheimer's Disease from Depression based on Structural MRI. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 353-363.	1.2	10
18	Association of Cerebral Amyloid- β^2 Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133

#	ARTICLE	IF	CITATIONS
19	P1â€298: CEREBROSPINAL FLUID AND PLASMA LEVELS OF LYSOPHOSPHATIDIC ACIDS (LPAS) ASSOCIATE WITH CEREBROSPINAL FLUID AÎ²â€42 AND τ . Alzheimer's and Dementia, 2018, 14, P403.	0.4	0
20	6.Diagnostische Methoden. , 2018, , 187-352.		0
21	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
22	The European DTI Study on Dementia â€” A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. NeuroImage, 2017, 144, 305-308.	2.1	33
23	Lateâ€onset major depression is associated with ageâ€related white matter lesions in the brainstem. International Journal of Geriatric Psychiatry, 2017, 32, 446-454.	1.3	7
24	Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning. Alzheimer's Research and Therapy, 2017, 9, 22.	3.0	31
25	Relation of Odor Identification with Alzheimerâ€™s Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	1.2	33
26	Memory Correlates of Alzheimerâ€™s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128.	1.2	27
27	Development of a Proxy-Free Objective Assessment Tool of Instrumental Activities of Daily Living in Mild Cognitive Impairment Using Smart Home Technologies. Journal of Alzheimer's Disease, 2016, 52, 509-517.	1.2	32
28	Electroconvulsive therapy selectively enhances amyloid Î² 1â€42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study. European Neuropsychopharmacology, 2016, 26, 1877-1884.	0.3	20
29	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
30	Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimerâ€™s Disease in Patients with Mild Cognitive Impairment â€” A Multicenter DTI and Volumetry Study. Journal of Alzheimer's Disease, 2015, 48, 197-204.	1.2	56
31	Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusionâ€Tensor and Magnetic Resonance Imaging Data. Journal of Neuroimaging, 2015, 25, 738-747.	1.0	79
32	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimer's Research and Therapy, 2015, 7, 17.	3.0	419
33	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
34	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.4	56
35	Detection of Retinal Nerve Fiber Layer Defects in Alzheimerâ€™s Disease Using SD-OCT. Frontiers in Psychiatry, 2014, 5, 22.	1.3	77
36	IC-P-072: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSO STUDY. , 2014, 10, P40-P40.		1

#	ARTICLE	IF	CITATIONS
37	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 53.	4.4	216
38	Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life. , 2014, 10, e27-e39.		9
39	Severe agitation in severe early-onset Alzheimer's disease resolves with ECT. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 2147.	1.0	14
40	P1-255: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSO STUDY. , 2014, 10, P400-P401.		1
41	Comparison of Visual Evoked Potentials and Retinal Nerve Fiber Layer Thickness in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2013, 4, 203.	1.1	21
42	Should electroconvulsive therapy be more routinely used in the treatment of depression in elderly patients with cognitive disturbances?. <i>Neuropsychiatry</i> , 2011, 1, 403-407.	0.4	1
43	Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) in Depressed Elderly Inpatients With Coexisting Mild Cognitive Impairment or Dementia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 91-97.	1.1	98
44	Regional Variation on the Presentation of Alzheimer's Disease Patients in Memory Clinics within Europe: Data from the ICTUS Study. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 155-165.	1.2	10